Participants in this study will be asked to give a small blood sample during a routine clinic check-up. Researchers will be looking at blood components and compare with expected venetoclax concentrations. The overall goal is to be able to use specific blood components ("biomarkers") to better optimize venetoclax doses for CLL patients.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Klarissa Jackson
UNC Eshelman School of Pharmacy-Division of Pharmacotherapy and Experimental Therapeutics
Clinical or Medical
Observational
Cancer (Leukemia)
20-1533
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
